| ISIN | LU2472219562 |
|---|---|
| Valor Number | |
| Bloomberg Global ID | |
| Fund Name | Galileo – Biotech Innovation Fund IM USD |
| Fund Provider |
IPConcept (Luxemburg) S.A.
Zürich, Switzerland Phone: +352 260248-1 E-Mail: info.lu@ipconcept.com Web: www.ipconcept.com |
| Fund Provider | IPConcept (Luxemburg) S.A. |
| Representative in Switzerland |
IPConcept (Schweiz) AG Zürich Phone: +41 044 224 32 09 |
| Distributor(s) | Bellecapital AG |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Luxembourg |
| Issuing Condition | The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets) |
| Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
| Investment Strategy *** | The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark. |
| Peculiarities |
| Current Price * | 122.34 USD | 28.11.2025 |
|---|---|---|
| Previous Price * | 122.24 USD | 27.11.2025 |
| 52 Week High * | 132.74 USD | 16.10.2025 |
| 52 Week Low * | 71.86 USD | 09.04.2025 |
| NAV * | 122.34 USD | 28.11.2025 |
| Issue Price * | 122.34 USD | 28.11.2025 |
| Redemption Price * | 122.34 USD | 28.11.2025 |
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 42,048,250 | |
| Unit/Share Assets *** | 506,539 | |
| Trading Information SIX | ||
| YTD Performance | +19.95% |
30.12.2024 - 28.11.2025
30.12.2024 28.11.2025 |
|---|---|---|
| YTD Performance (in CHF) | +6.52% |
30.12.2024 - 28.11.2025
30.12.2024 28.11.2025 |
| 1 month | -6.12% |
28.10.2025 - 28.11.2025
28.10.2025 28.11.2025 |
| 3 months | +25.07% |
28.08.2025 - 28.11.2025
28.08.2025 28.11.2025 |
| 6 months | +49.74% |
28.05.2025 - 28.11.2025
28.05.2025 28.11.2025 |
| 1 year | +3.49% |
28.11.2024 - 28.11.2025
28.11.2024 28.11.2025 |
| 2 years | +9.76% |
28.11.2023 - 28.11.2025
28.11.2023 28.11.2025 |
| 3 years | -21.74% |
28.11.2022 - 28.11.2025
28.11.2022 28.11.2025 |
| 5 years | -18.44% |
31.05.2022 - 28.11.2025
31.05.2022 28.11.2025 |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Krystal Biotech Inc | 8.74% | |
|---|---|---|
| Arcellx Inc | 8.63% | |
| Vertex Pharmaceuticals Inc | 5.91% | |
| Alnylam Pharmaceuticals Inc | 5.75% | |
| BioNTech SE ADR | 4.80% | |
| Regeneron Pharmaceuticals Inc | 3.82% | |
| Stoke Therapeutics Inc | 3.67% | |
| Gilead Sciences Inc | 3.11% | |
| AbbVie Inc | 2.88% | |
| Bristol-Myers Squibb Co | 2.75% | |
| Last data update | 30.04.2025 | |
| TER | |
|---|---|
| TER date | |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 1.25% |
| Ongoing Charges *** | 1.71% |
|
SRRI ***
|
|
| SRRI date *** | 31.10.2025 |